drugset / Trial / NCT00003457
Antineoplaston Therapy in Treating Patients With Brain Tumors
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with persistent or recurrent brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with persistent or recurrent brain tumors.
Timeline
- Start
- 1996-07
- Primary completion
- 2012-02
- Completion
- 2012-02
Publications
- Background Burzynski SR, Janicki TJ, Burzynski GS. A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors-Final Report (Protocol BT-09). Journal of Cancer Therapy 6(12): 1063-1074, 2015. DOI: 10.4236/jct.2015.612116
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Astugenal | Unknown | — | Intravenous |
| Subject | antineoplaston A10 | Small molecule | — | Intravenous |